Abstract
Male infertility is a prevalent condition, concerning 5-10% of men. So far, only some recurrent genetic factors have been described as confident contributors to spermatogenic failure. Here, we report the first re-sequencing study of the Y-chromosomal Azoospermia Factor c (AZFc) region combined with gene dosage and Y-haplogroup determination. In analysing 2,324 Estonian men, we uncovered a novel structural variant as a high-penetrant risk factor to male infertility. The Y lineage R1a1-M458, reported at >20% frequency in several European populations, carries a fixed ∼1.6 Mb long r2/r3 inversion destabilizing the AZFc region and predisposing to recurrent microdeletions. Such complex rearrangements were significantly enriched among severe oligozoospermia cases. The carrier vs non-carrier risk to spermatogenic failure was increased 8.6-fold (p = 6.0 × 10−4). The finding contributes to improved molecular diagnostics and clinical management of infertility. Carrier identification in young age will facilitate timely counselling and reproductive decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Our work was supported by the Wellcome Trust (098051). P.H. and L.K. were supported by Estonian Research Council Grant PUT1036 and M.P. and O.P. by PUT181. L.K., M.G., K.R. and M.L. were supported by Estonian Research Council Project IUT34-12, R.F. by IUT24-1 and S.R. by IUT24-1 and MOBTT53. Establishment of the cohort of Estonian infertility subjects was also supported by the EU through the European Regional Development Fund, project HAPPY PREGNANCY, no. 3.2.0701.12-004 (M.L., M.P., K.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (permissions 146/18, 152/4, 221/T-6, 221/M-5, 272/M-13, 267M-13, 286M-18, 288M-13), and sequencing/genotyping was approved at the Wellcome Sanger Institute under WTSI HMDMC 17/105.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Illumina MiSeq re-sequencing data are available through the European Genome-phenome Archive (EGA, https://www.ebi.ac.uk/) under the accession number: EGAS00001002157